ΠΦΥ -Εκπαίδευση > Συζητήσεις πάνω σε ιατρικά θέματα
Κορονοϊός ( COVID-19 )
Argirios Argiriou:
14/04/2022
Φάουτσι: Τα κρούσματα κορωνοϊού αυξάνονται - O κόσμος άνω των 50 να κάνει τέταρτη δόση
Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή Είσοδος
Argirios Argiriou:
15/04/2022
Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή Είσοδος
Argirios Argiriou:
17/04/2022
Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή Είσοδος
Argirios Argiriou:
Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή Είσοδος
Argirios Argiriou:
April 21, 2022
Myopericarditis Risk After COVID-19 and Other Vaccines
Harlan M. Krumholz, MD, SM, reviewing Ling RR et al. Lancet Respir Med 2022 Apr 11
In a meta-analysis, there was no significant difference in incidence after COVID-19 vaccinations versus non–COVID-19 vaccinations.
A small increased risk for myopericarditis after COVID-19 vaccination is shown in case reports and population-based studies. To characterize this risk further, particularly in subpopulations, investigators conducted a systematic review and meta-analysis of this complication after both COVID-19 and non–COVID-19 vaccines.
They evaluated 22 studies comprising more than 400 million vaccine doses administered to general populations. Results were as follows:
Risk for myopericarditis was 33 cases per million vaccine doses and did not differ significantly by whether it was a COVID vaccine (18 cases per million doses) or non–COVID-19 vaccine (56 per million).
Myopericarditis risk was lower after COVID vaccination than after smallpox vaccination but not significantly different from risk after influenza vaccination.
In COVID-19 vaccine studies, risk was higher in males, those younger than 30, mRNA vaccine recipients, and those receiving a second dose (vs. first or third dose). For those under 30 years, the risk in males was ten times higher than that in females.
Based on 10 studies, the pooled all-cause mortality following vaccination was 7.8 deaths per million doses, which was not significantly different between COVID-19 and non–COVID-19 vaccines.
COMMENT
This review adds a new twist. While data have consistently shown that myopericarditis rates are low and concentrated in younger people and males, this study adds the comparison with non–COVID-19 vaccines and shows no significant difference in overall rates.
CITATIONS
Ling RR et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: A systematic review and meta-analysis. Lancet Respir Med 2022 Apr 11; [e-pub]. (Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή Είσοδος. opens in new tab)
Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή Είσοδος
Πλοήγηση
[0] Λίστα μηνυμάτων
[#] Επόμενη σελίδα
Μετάβαση στην πλήρη έκδοση